The decision to discontinue tigecycline may be prompted by increases in liver function tests, particularly elevated bilirubin levels [1]. Tigecycline carries a black box warning for increased mortality in certain serious infections, and liver toxicity is a noted adverse event.
What liver function tests indicate a problem with tigecycline?
Elevated bilirubin, which can lead to jaundice, is a key indicator that warrants further evaluation when a patient is on tigecycline [1]. While other liver enzymes might also be affected, significant increases in bilirubin are particularly concerning and can necessitate stopping the medication [1].
When should tigecycline be stopped due to liver issues?
If a patient receiving tigecycline develops severe hyperbilirubinemia (significantly elevated bilirubin), discontinuing the drug should be considered [1]. The clinical significance of less severe elevations should be weighed against the benefits of continuing tigecycline for the infection being treated [1].
What are the risks associated with tigecycline?
Tigecycline is associated with a black box warning regarding increased mortality in patients treated for serious infections, including hospital-acquired bacterial pneumonia and complicated skin and skin structure infections. This warning is based on clinical trial data where tigecycline was associated with a higher death rate compared to other active comparators [2]. Beyond increased mortality, other serious adverse events can occur, including gastrointestinal issues like nausea, vomiting, and diarrhea, as well as pancreatitis and the potential for liver toxicity [1, 3].
How does tigecycline's liver toxicity compare to other antibiotics?
While specific direct comparisons of liver toxicity between tigecycline and all other antibiotics are complex and depend on the drug class and patient population, tigecycline's labeling explicitly mentions the risk of hyperbilirubinemia and hepatic adverse events [1, 3]. Other antibiotics can also cause liver injury, but the presentation and frequency may differ. For instance, some fluoroquinolones or macrolides can also be associated with liver enzyme elevations [4].
What are the alternatives to tigecycline for serious infections?
Treatment decisions depend heavily on the specific pathogen, its susceptibility, the site of infection, and patient factors. For Gram-negative infections, alternatives might include carbapenems, extended-spectrum cephalosporins with beta-lactamase inhibitors, or newer agents depending on resistance patterns [5]. For certain Gram-positive infections, options could include vancomycin, daptomycin, or linezolid [5]. The choice of an alternative would be guided by antibiograms and clinical guidelines for the specific infection.
Where can I find more information on drug patents and exclusivity?
Information on drug patents, including their expiry dates and potential challenges, can be found on DrugPatentWatch.com [6]. This resource tracks patent information for pharmaceutical products, which is crucial for understanding market exclusivity and the potential entry of generic or biosimilar competitors.
Sources
1. Tigecycline prescribing information
2. Tygacil® Prescribing Information
3. Tigecycline (Tygacil)
4. Drug-induced liver injury
5. Clinical Practice Guidelines by the Infectious Diseases Society of America
6. DrugPatentWatch.com